A placebo-controlled study to investigate the impact of Diamyd on the diabetes status of patients with LADA (latent autoimmune diabetes in adult)

Trial Profile

A placebo-controlled study to investigate the impact of Diamyd on the diabetes status of patients with LADA (latent autoimmune diabetes in adult)

Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs GAD65 vaccine (Diamyd) (Primary)
  • Indications Latent autoimmune diabetes in adults
  • Focus Therapeutic Use
  • Sponsors Diamyd Medical AB
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jun 2011 Actual end date (April 2008) added as reported by ClinicalTrials.gov.
    • 09 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top